Published on June 14, 2012 at 7:02 AM
Aeris Therapeutics, LLC announced that the U.S. Patent and Trademark
Office has issued a patent covering the use of cross-linked polymers
administered into the lung to reduce lung volume for the treatment of
emphysema. This newly issued patent, entitled "Lung Volume Reduction
Therapy Using Crosslinked Non-Natural Polymers," covers novel technology
that enables lung volume reduction therapy without high risk surgery.
"The issuance of this patent is an important step forward in
strengthening the intellectual property covering the AeriSeal® System
and Aeris' position as the leader in endoscopic lung volume reduction,"
commented David Dove, MD, CEO of Aeris. "Designing and protecting
innovative methods of treating emphysema is critical to our mission of
advancing new therapies that improve the lives of patients with advanced
lung disease into clinical use."
Source: Aeris Therapeutics